Potential Conflict of Interest: The following list is a reflection of what has been reported to IDSA. To provide thorough transparency, IDSA requires full disclosure of all relationships, regardless of relevancy to the guideline topic. Evaluation of such relationships as potential conflicts of interest (COI) is determined by a review process that includes assessment by the SPGC Chair, the SPGC liaison to the development Panel, the Board of Directors liaison to the SPGC, and, if necessary, the Conflict of Interest (COI) Task Force of the Board. This assessment of disclosed relationships for possible COI will be based on the relative weight of the financial relationship (i.e., monetary amount) and the relevance of the relationship (i.e., the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. For activities outside of the submitted work, N.A. has received payment from Up to Date. For activities outside of the submitted work M.E. has received research grants from the Israel National Institute for Health Policy Research (Rotavirus). For activities outside of the submitted work, R.P. has received personal fees from Merck & Co, Inc. and has a patent Protozoacidal Activity of the Phenothiazines (U.S. patent number 4,407,800), 1983.issued. No conflicts: E.C., M.L., R.L., B.H., P.W., S.J., and A.M.